Imaxio and Centre Léon Bérard announce the execution of a collaboration agreement and the award of a grant for the preclinical development of an anticancer immunotherapy based on the Imaxio’s IMX313 technology.
The grant has been awarded as part of the funding program “Proof of Concept CLARA” from the Cancéropôle Lyon Auvergne-Rhône-Alpe.
Lyon, France - 3rd October 2016 – Imaxio, a biotech company specialized in immunology, announces today the execution of a collaboration agreement with Centre Léon Bérard, and the award of a grant, as part of the program “Proof of Concept CLARA” from the Cancéropôle Lyon Auvergne-Rhône-Alpes (CLARA), to finance the ORPhEE project.
The ORPhEE project, “non-antigen specific intratumoral immunostimulation”, is an initiative of both Imaxio and its partner Centre Léon Bérard (Comprehensive Cancer Center), also based in Lyon. Its objective is to achieve the preclinical development, within the next 30 months, of an immunotherapy used to improve current anticancer therapies by leveraging on the pro-immunogenic effect of Imaxio’s IMX313 technology. ORPhEE’s budget will benefit, through the program Proof of Concept CLARA, from the support of Lyon Metropole up to 354 k€.